Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JUN | P05412 | 1/20 | 0.56 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.56 |
| ▸ | UGT1A3 | P35503 | 1/20 | 0.56 |
| ▸ | UGT1A8 | Q9HAW9 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2967854 | 0.93 | JUN (0.59) | JUNUGT1A1UGT1A3UGT1A8MAPT | |
| SCHEMBL2964477 | 0.92 | JUN (0.59) | JUNUGT1A1UGT1A3UGT1A8LMNA | |
| SCHEMBL2965022 | 0.92 | JUN (0.61) | JUNUGT1A1UGT1A3UGT1A8LMNA | |
| SCHEMBL2967226 | 0.90 | JUN (0.69) | JUNUGT1A1UGT1A3UGT1A8LMNA | |
| SCHEMBL2966996 | 0.88 | JUN (0.55) | JUNUGT1A1UGT1A3UGT1A8FFAR1 | |
| SCHEMBL2963604 | 0.87 | JUN (0.53) | JUNUGT1A1UGT1A3UGT1A8LMNA | |
| SCHEMBL2959189 | 0.86 | JUN (0.54) | JUNUGT1A1UGT1A3UGT1A8FFAR1 | |
| SCHEMBL2959105 | 0.86 | JUN (0.54) | JUNUGT1A1UGT1A3UGT1A8FFAR1 | |
| SCHEMBL6923825 | 0.84 | JUN (0.56) | JUNUGT1A1UGT1A3UGT1A8LMNA | |
| SCHEMBL1100281 | 0.83 | JUN (0.64) | JUNUGT1A1UGT1A3UGT1A8LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1445249-B1 | NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-7772285-B2 | Benzophenone derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20050113400-A1 | Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo | SHUNICHI SHIOZAWA (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1445249-A1 | NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113400-A1 | Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo | SP1, AP1G1, JUN | JUN 3/4885UGT1A1 1244/4885UGT1A3 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.